ABC294640 in Treating Patients With Advanced Solid Tumors
Summary
This phase I trial studies the side effects and best dose of ABC294640 in treating patients with advanced solid tumors. ABC294640 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Please note that the FDA OOPD is participating as a funding source.
Timeline
- Start
- 2011-08
- Primary completion
- 2014-08
- Completion
- 2015-07
Outcome
Met primary endpoint
release “The Phase I study with YELIVA™ (ABC294640) successfully met its primary and secondary endpoints” redhillbio.com ↗
release “The Phase I study with YELIVA® in patients with advanced solid tumors successfully met its primary and secondary endpoints” redhillbio.com ↗
release “a Phase I clinical study with YELIVA® in patients with advanced solid tumors which successfully met its primary and secondary endpoints” redhillbio.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABC294640 | Small molecule | 250 mg | Oral |
| Subject | ABC294640 | Small molecule | 500 mg | Oral |
| Subject | ABC294640 | Small molecule | 750 mg | Oral |
| Subject | ABC294640 | Small molecule | 1000 mg | Oral |
| Subject | ABC294640 | Small molecule | 1500 mg | Oral |
| Subject | ABC294640 | Small molecule | 2000 mg | Oral |
| Subject | ABC294640 | Small molecule | 2500 mg | Oral |